Sarepta Therapeutics Inc. research and ratings by Barron's. View SRPT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

This afternoon we watched Sarepta Therapeutics rise 5.6% to a price of $58.34 per share. The Mid-Cap Pharmaceutical company is now trading -60.85% below its average target price of $149.0. Analysts ...

PhaseV, a leader in AI/ML-driven clinical development, today announced that the second episode in its webinar series will focus on improving patient-centricity and efficiency in clinical trial design.

FAIR Health released the second edition of the Monthly Telehealth Regional Tracker Trending Reports, a free set of infographics that show national and regional trends in telehealth from July to ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: ...

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Shares of Intellia Therapeutics (NASDAQ:NTLA) were up over 10% on Monday, after Wolfe Research upgraded the company to Outperform from Peer Perform.

Piper Sandler lowered the firm’s price target on Sarepta (SRPT) to $110 from $182 and keeps an Overweight rating on the shares. The firm is ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apellis Pharmaceuticals (APLS – Research Report), Skye ...